Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc.BBOT · Entity 5215 | Director | June 16, 2026 | June 18, 2026 |
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director · Chief Executive Officer | September 17, 2026 | September 21, 2026 |
| Eidos Therapeutics, Inc.EIDX · Entity 143355 | Director · Chief Executive Officer · 10% owner | July 03, 2019 | July 09, 2019 |
| LianBioLIAN · Entity 9881 | Director | October 29, 2021 | November 09, 2021 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Director | March 27, 2026 | March 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Oncology Therapeutics, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.73 · Expires 2036-06-15 | Direct | 31,675 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 31,675 · Balance 31,675 F1: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
BridgeBio Pharma, Inc.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | 495,686 |
Last balance in matching sequence
After 2026-09-17 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-17 · Sale · Disposed 8,721 · Balance 496,965 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F2: Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Row 2 · 2026-09-17 · Sale · Disposed 1,279 · Balance 495,686 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F4: Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | 3,568,447 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,568,447 F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy NK 2026 GRAT | 750,000 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 750,000 F5: These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 243,327 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 243,327 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026.
F2: Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F4: Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F5: These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.
Eidos Therapeutics, Inc.
Report date July 03, 2019 · Filed July 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 24,575,501 |
Reported balance
After 2019-07-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-07-03 · Purchase · Acquired 882,353 · Balance 24,575,501 F1: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.
LianBio
Report date October 29, 2021 · Filed November 09, 2021 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy BridgeBio Pharma LLC | 5,002,792 |
Reported balance
Holding disclosure · report date 2021-10-29 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 5,002,792 F1: The shares are held by BridgeBio Pharma LLC, a wholly-owned subsidiary of BridgeBio Pharma, Inc. Dr. Neil Kumar is the President and Chief Executive Officer and a director of BridgeBio Pharma, Inc., and as a result may be deemed to share voting and investing power over these Ordinary Shares. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by BridgeBio Pharma LLC, a wholly-owned subsidiary of BridgeBio Pharma, Inc. Dr. Neil Kumar is the President and Chief Executive Officer and a director of BridgeBio Pharma, Inc., and as a result may be deemed to share voting and investing power over these Ordinary Shares. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Maze Therapeutics, Inc.
Report date March 27, 2026 · Filed March 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.38 · Expires 2036-03-26 | Direct | 33,417 |
Reported balance
After 2026-03-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-27 · Grant · Acquired 33,417 · Balance 33,417 F1: The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on April 27, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on April 27, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 06, 2025 Filed Nov 10, 2025 22:33 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 100 | $64.39 | $6,439.00 |
DisclosureSEC source: 0001470831-25-000302 · wk-form4_1762814033.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,618,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 22:33 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 7,324 | $63.55 | $465,416.03 |
DisclosureSEC source: 0001470831-25-000302 · wk-form4_1762814033.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,618,547 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $63.25 to $64.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 22:33 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 12,576 | $62.91 | $791,166.22 |
DisclosureSEC source: 0001470831-25-000302 · wk-form4_1762814033.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,625,871 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $62.245 to $63.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 21:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 20,000 | $54.80 | $1,096,046.00 |
DisclosureSEC source: 0001470831-25-000256 · wk-form4_1760132409.xml · nonDerivative · entry 6 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 835,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F5 · price: Represents the weighted average sale price of the shares sold from $54.49 to $55.28 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 21:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 20,000 | $54.80 | $1,096,046.00 |
DisclosureSEC source: 0001470831-25-000256 · wk-form4_1760132409.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,638,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F5 · price: Represents the weighted average sale price of the shares sold from $54.49 to $55.28 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 21:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 11,295 | $55.09 | $622,225.74 |
DisclosureSEC source: 0001470831-25-000256 · wk-form4_1760132409.xml · nonDerivative · entry 5 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 855,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $54.82 to $55.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 21:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 8,705 | $54.39 | $473,450.15 |
DisclosureSEC source: 0001470831-25-000256 · wk-form4_1760132409.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 866,981 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $53.82 to $54.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 21:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 11,294 | $55.09 | $622,170.65 |
DisclosureSEC source: 0001470831-25-000256 · wk-form4_1760132409.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,658,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $54.82 to $55.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 21:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 8,706 | $54.39 | $473,503.67 |
DisclosureSEC source: 0001470831-25-000256 · wk-form4_1760132409.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,669,741 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $53.82 to $54.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 800 | $53.80 | $43,039.52 |
DisclosureSEC source: 0001742485-25-000005 · wk-form4_1757369131.xml · nonDerivative · entry 10 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 875,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F11 · price: Represents the weighted average sale price of the shares sold from $53.66 to $53.91 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 16,900 | $53.16 | $898,449.63 |
DisclosureSEC source: 0001742485-25-000005 · wk-form4_1757369131.xml · nonDerivative · entry 9 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 876,486 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F6 · price: Represents the weighted average sale price of the shares sold from $52.65 to $53.62 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,300 | $51.96 | $119,513.75 |
DisclosureSEC source: 0001742485-25-000005 · wk-form4_1757369131.xml · nonDerivative · entry 8 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 893,386 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F10 · price: Represents the weighted average sale price of the shares sold from $51.64 to $52.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 900 | $53.80 | $48,423.96 |
DisclosureSEC source: 0001742485-25-000005 · wk-form4_1757369131.xml · nonDerivative · entry 5 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,678,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F7 · price: Represents the weighted average sale price of the shares sold from $53.70 to $53.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 16,800 | $53.16 | $893,124.96 |
DisclosureSEC source: 0001742485-25-000005 · wk-form4_1757369131.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,679,347 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F6 · price: Represents the weighted average sale price of the shares sold from $52.65 to $53.62 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,300 | $51.95 | $119,495.58 |
DisclosureSEC source: 0001742485-25-000005 · wk-form4_1757369131.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,696,147 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F5 · price: Represents the weighted average sale price of the shares sold from $51.58 to $52.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 5,442 | $51.85 | $282,186.75 |
DisclosureSEC source: 0001742485-25-000005 · wk-form4_1757369131.xml · nonDerivative · entry 7 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 895,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F9 · price: Represents the weighted average sale price of the shares sold from $51.52 to $52.35 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 14,558 | $51.16 | $744,739.24 |
DisclosureSEC source: 0001742485-25-000005 · wk-form4_1757369131.xml · nonDerivative · entry 6 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 901,128 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F8 · price: Represents the weighted average sale price of the shares sold from $50.52 to $51.49 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 5,475 | $51.85 | $283,902.29 |
DisclosureSEC source: 0001742485-25-000005 · wk-form4_1757369131.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,698,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $51.53 to $52.35 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 14,525 | $51.15 | $742,959.56 |
DisclosureSEC source: 0001742485-25-000005 · wk-form4_1757369131.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,703,922 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $50.53 to $51.52 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| August 20, 2025 Filed Aug 22, 2025 20:46 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 428 | $49.25 | $21,079.17 |
DisclosureSEC source: 0000950170-25-110993 · ownership.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 223,090 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $49.22 to $49.26 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 20, 2025 Filed Aug 22, 2025 20:46 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 25,728 | $48.81 | $1,255,848.00 |
DisclosureSEC source: 0000950170-25-110993 · ownership.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 223,518 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $48.22 to $49.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 16, 2025 Filed Aug 19, 2025 23:38 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 11,554 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-110271 · ownership.xml · derivative · entry 7 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,753 Underlying: Common Stock · 11,554 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F6 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2025 Filed Aug 19, 2025 23:38 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 19,599 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-110271 · ownership.xml · derivative · entry 6 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,993 Underlying: Common Stock · 19,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F5 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2025 Filed Aug 19, 2025 23:38 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 33,544 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-110271 · ownership.xml · derivative · entry 5 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,264 Underlying: Common Stock · 33,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F4 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2025 Filed Aug 19, 2025 23:38 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 32,855 | $51.32 | $1,686,118.60 |
DisclosureSEC source: 0000950170-25-110271 · ownership.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,246 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 64,697 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| August 16, 2025 Filed Aug 19, 2025 23:38 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 64,697 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-110271 · ownership.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 08, 2025 Filed Aug 11, 2025 22:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 8,205 | $46.71 | $383,252.27 |
DisclosureSEC source: 0000950170-25-106741 · ownership.xml · nonDerivative · entry 8 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 915,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F5 · price: Represents the weighted average sale price of the shares sold from $46.49 to $47.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 08, 2025 Filed Aug 11, 2025 22:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 11,795 | $45.88 | $541,161.68 |
DisclosureSEC source: 0000950170-25-106741 · ownership.xml · nonDerivative · entry 7 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 923,891 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $45.49 to $46.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 08, 2025 Filed Aug 11, 2025 22:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 8,205 | $46.71 | $383,252.27 |
DisclosureSEC source: 0000950170-25-106741 · ownership.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,718,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F5 · price: Represents the weighted average sale price of the shares sold from $46.49 to $47.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 08, 2025 Filed Aug 11, 2025 22:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 11,795 | $45.88 | $541,161.68 |
DisclosureSEC source: 0000950170-25-106741 · ownership.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,726,652 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $45.49 to $46.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 22:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 13,216 | $45.64 | $603,151.81 |
DisclosureSEC source: 0000950170-25-106741 · ownership.xml · nonDerivative · entry 6 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 935,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F3 · price: Represents the weighted average sale price of the shares sold from $45.31 to $46.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 22:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 6,784 | $45.09 | $305,908.88 |
DisclosureSEC source: 0000950170-25-106741 · ownership.xml · nonDerivative · entry 5 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 948,902 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $44.31 to $45.305 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 22:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 13,216 | $45.64 | $603,151.81 |
DisclosureSEC source: 0000950170-25-106741 · ownership.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,738,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F3 · price: Represents the weighted average sale price of the shares sold from $45.31 to $46.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 22:12 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 6,784 | $45.09 | $305,908.88 |
DisclosureSEC source: 0000950170-25-106741 · ownership.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,751,663 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $44.31 to $45.305 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| July 02, 2025 Filed Jul 3, 2025 20:30 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 20,000 | $42.73 | $854,514.00 |
DisclosureSEC source: 0000950170-25-093907 · ownership.xml · nonDerivative · entry 6 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 955,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F8 · price: Represents the weighted average sale price of the shares sold from $42.22 to $43.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| July 02, 2025 Filed Jul 3, 2025 20:30 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 20,000 | $42.73 | $854,536.00 |
DisclosureSEC source: 0000950170-25-093907 · ownership.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,758,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F5 · price: Represents the weighted average sale price of the shares sold from $42.145 to $43.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:30 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,600 | $42.89 | $68,628.00 |
DisclosureSEC source: 0000950170-25-093907 · ownership.xml · nonDerivative · entry 5 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 975,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F7 · price: Represents the weighted average sale price of the shares sold from $42.81 to $42.98 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:30 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 18,400 | $42.51 | $782,092.00 |
DisclosureSEC source: 0000950170-25-093907 · ownership.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 977,286 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F6 · price: Represents the weighted average sale price of the shares sold from $41.81 to $42.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:30 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,700 | $42.88 | $72,902.97 |
DisclosureSEC source: 0000950170-25-093907 · ownership.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,778,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F4 · price: Represents the weighted average sale price of the shares sold from $42.81 to $42.96 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:30 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 18,300 | $42.50 | $777,777.45 |
DisclosureSEC source: 0000950170-25-093907 · ownership.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,780,147 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F2 · price: Represents the weighted average sale price of the shares sold from $41.80 to $42.79 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 20, 2025 Filed May 20, 2025 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 75,000 | $33.40 | $2,504,977.50 |
DisclosureSEC source: 0000950170-25-075425 · ownership.xml · nonDerivative · entry 5 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,798,447 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F6 · price: Represents the weighted average sale price of the shares sold from $33.02 to $33.66 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F7 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 19, 2025 Filed May 20, 2025 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 400 | $33.75 | $13,499.00 |
DisclosureSEC source: 0000950170-25-075425 · ownership.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 217,404 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F5 · price: Represents the weighted average sale price of the shares sold from $33.72 to $33.79 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| May 19, 2025 Filed May 20, 2025 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 25,756 | $33.32 | $858,264.61 |
DisclosureSEC source: 0000950170-25-075425 · ownership.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 217,804 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F4 · price: Represents the weighted average sale price of the shares sold from $32.72 to $33.71 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| May 16, 2025 Filed May 20, 2025 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 11,553 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-075425 · ownership.xml · derivative · entry 9 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,307 Underlying: Common Stock · 11,553 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F10 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F10 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2025 Filed May 20, 2025 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 19,599 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-075425 · ownership.xml · derivative · entry 8 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,592 Underlying: Common Stock · 19,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F9 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F9 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2025 Filed May 20, 2025 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 33,544 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-075425 · ownership.xml · derivative · entry 7 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 234,808 Underlying: Common Stock · 33,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F8 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2025 Filed May 20, 2025 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 32,854 | $33.84 | $1,111,779.36 |
DisclosureSEC source: 0000950170-25-075425 · ownership.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 243,560 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 64,696 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| May 16, 2025 Filed May 20, 2025 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 64,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-075425 · ownership.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| April 22, 2025 Filed Apr 24, 2025 20:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 75,000 | $34.11 | $2,558,025.00 |
DisclosureSEC source: 0000950170-25-058102 · ownership.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,873,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F2 · price: Represents the weighted average sale price of the shares sold from $33.56 to $34.44 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| March 25, 2025 Filed Mar 27, 2025 20:54 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 75,000 | $36.87 | $2,764,942.50 |
DisclosureSEC source: 0000950170-25-046171 · ownership.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,948,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F2 · price: Represents the weighted average sale price of the shares sold from $36.55 to $37.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.